FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Chris Feierabend

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Daniel Mulkerin; N K LoConte; K D Holen; James P Thomas; Dona Alberti; Rebecca Marnocha; Jill M Kolesar; Jens Eickhoff; K Oliver; Chris Feierabend; George Wilding
A phase I study of an oral simulated FOLFOX with high dose capecitabine.
Sarita Dubey; Paul Hutson; Dona Alberti; Rhoda Arzoomanian; Kim Binger; Jennifer Volkman; Chris Feierabend; George Wilding; Joan H Schiller
Phase I study of docetaxel and topotecan in patients with advanced malignancies.
Howard H Bailey; George Wilding; Kendra Tutsch; Rhoda Arzoomanian; Dona Alberti; Chris Feierabend; Kris Simon; Rebecca Marnocha; Sarah A Holstein; Jan Stewart; Kriste A Lewis; Raymond J Hohl
A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Chris Feierabend (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Daniel Mulkerin; N K LoConte; K D Holen; James P Thomas; Dona Alberti; Rebecca Marnocha; Jill M Kolesar; Jens Eickhoff; K Oliver; Chris Feierabend; George Wilding
A phase I study of an oral simulated FOLFOX with high dose capecitabine.
Investigational new drugs 2009;27(5):461-8.
2005: Sarita Dubey; Paul Hutson; Dona Alberti; Rhoda Arzoomanian; Kim Binger; Jennifer Volkman; Chris Feierabend; George Wilding; Joan H Schiller
Phase I study of docetaxel and topotecan in patients with advanced malignancies.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2005;11(4):131-8.
2004: Howard H Bailey; George Wilding; Kendra Tutsch; Rhoda Arzoomanian; Dona Alberti; Chris Feierabend; Kris Simon; Rebecca Marnocha; Sarah A Holstein; Jan Stewart; Kriste A Lewis; Raymond J Hohl
A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.
Cancer chemotherapy and pharmacology 2004;54(4):368-76.
2004: Craig A Schulz; Minesh Mehta; Behnam Badie; Cornelius J McGinn; H Ian Robins; Lori Hayes; Richard J Chappell; Jennifer Volkman; Kim Binger; Rhoda Arzoomanian; Kris Simon; Dona Alberti; Chris Feierabend; Kendra Tutsch; Keith A Kunugi; George Wilding; Timothy J Kinsella
Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.
International journal of radiation oncology, biology, physics 2004;59(4):1107-15.
2004: George Wilding; David King; Kendra Tutsch; Marcia Pomplun; Chris Feierabend; Dona Alberti; Rhoda Arzoomanian
Phase I trial of the polyamine analog N1,N14-diethylhomospermine (DEHSPM) in patients with advanced solid tumors.
Investigational new drugs 2004;22(2):131-8.
2003: Sherry Morgan-Meadows; Sarita Dubey; Michael Gould; Kendra Tutsch; Rebecca Marnocha; Rhoda Arzoomanin; Dona Alberti; Kim Binger; Chris Feierabend; Jennifer Volkman; Shawna Ellingen; Sandra Black; Marcia Pomplun; George Wilding; Howard H Bailey
Phase I trial of perillyl alcohol administered four times daily continuously.
Cancer chemotherapy and pharmacology 2003;52(5):361-6.
2003: Glenn Liu; Howard H Bailey; Rhoda Arzoomanian; Dona Alberti; Kim Binger; Jennifer Volkman; Chris Feierabend; Rebecca Marnocha; George Wilding; James P Thomas
Gemcitabine, Paclitaxel, and piritrexim: a phase I study.
American journal of clinical oncology 2003;26(3):280-4.
2002: James P Thomas; Kendra Tutsch; James F Cleary; Howard H Bailey; Rhoda Arzoomanian; Dona Alberti; Kris Simon; Chris Feierabend; Kim Binger; Rebecca Marnocha; Amy Dresen; George Wilding
Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
Cancer chemotherapy and pharmacology 2002;50(6):465-72.
2002: Sherry Morgan-Meadows; James P Thomas; Daniel Mulkerin; Jordan D Berlin; Howard H Bailey; Kim Binger; Jennifer Volkman; Dona Alberti; Chris Feierabend; Rebecca Marrocha; Rhoda Arzoomanian; George Wilding
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.
Investigational new drugs 2002;20(4):377-82.
2002: Joseph Merchant; Kendra Tutsch; Amy Dresen; Rhoda Arzoomanian; Dona Alberti; Chris Feierabend; Kim Binger; Rebecca Marnoccha; James P Thomas; Jim Cleary; George Wilding
Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2193-201.
2002: Glenn Liu; Jordan Berlin; Kendra Tutsch; Lynn Van Ummersen; Amy Dresen; Rebecca Marnocha; Rhoda Arzomanian; Dona Alberti; Chris Feierabend; Kim Binger; George Wilding
Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):706-11.
2002: Jordan Berlin; Kendra Tutsch; Rhoda Arzoomanian; Dona Alberti; Kim Binger; Chris Feierabend; Amy Dresen; Rebecca Marnocha; James Pluda; George Wilding
Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):86-94.
2001: James P Thomas; Rhoda Arzoomanian; Dona Alberti; Chris Feierabend; Kim Binger; Kendra Tutsch; T Steele; Rebecca Marnocha; C Smith; S Smith; J MacDonald; George Wilding; Howard H Bailey
Phase I clinical and pharmacokinetic trial of irofulven.
Cancer chemotherapy and pharmacology 2001;48(6):467-72.
2000: Gregory Ripple; M N Gould; Rhoda Arzoomanian; Dona Alberti; Chris Feierabend; Kris Simon; Kim Binger; Kendra Tutsch; Marcia Pomplun; A Wahamaki; Rebecca Marnocha; George Wilding; Howard H Bailey
Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):390-6.
1999: H Ian Robins; Kendra Tutsch; Dörthe M Katschinski; E Jacobson; Minesh Mehta; M Olsen; J D Cohen; CL Tiggelaar; Rhoda Arzoomanian; Dona Alberti; Chris Feierabend; George Wilding
Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2922-31.
1999: Kendra Tutsch; Rhoda Arzoomanian; Dona Alberti; Mary Beth Tombes; Chris Feierabend; H Ian Robins; David Spriggs; George Wilding
Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812).
Investigational new drugs 1999;17(1):63-72.
1999: H Ian Robins; Dörthe M Katschinski; W Longo; Elizabeth A Grosen; George Wilding; W Gillis; C Kraemer; CL Tiggelaar; D Rushing; James A Stewart; David Spriggs; R Love; Rhoda Arzoomanian; Chris Feierabend; Dona Alberti; K Morgan; Kris Simon; FR d'Oleire
A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees C whole-body hyperthermia.
Cancer chemotherapy and pharmacology 1999;43(5):409-14.
1998: Gregory Ripple; M N Gould; James A Stewart; Kendra Tutsch; Rhoda Arzoomanian; Dona Alberti; Chris Feierabend; Marcia Pomplun; George Wilding; Howard H Bailey
Phase I clinical trial of perillyl alcohol administered daily.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1159-64.
1998: Jordan Berlin; James A Stewart; B Storer; Kendra Tutsch; Rhoda Arzoomanian; Dona Alberti; Chris Feierabend; Kris Simon; George Wilding
Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):1142-9.
1998: Jordan D Berlin; Dona Alberti; Rhoda Arzoomanian; Chris Feierabend; K J Simon; Kim Binger; Rebecca Marnocha; George Wilding
A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors.
Investigational new drugs 1998;16(4):325-30.
1997: Howard H Bailey; Gregory Ripple; Kendra Tutsch; Rhoda Arzoomanian; Dona Alberti; Chris Feierabend; D Mahvi; Julian C Schink; Marcia Pomplun; R Timothy Mulcahy; George Wilding
Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.
Journal of the National Cancer Institute 1997;89(23):1789-96.
1997: Jordan Berlin; Kendra Tutsch; P Hutson; J Cleary; RP Rago; Rhoda Arzoomanian; Dona Alberti; Chris Feierabend; George Wilding
Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):781-9.
1997: James F Cleary; Rhoda Arzoomanian; Dona Alberti; Chris Feierabend; B Storer; P Witt; PP Carbone; George Wilding
A phase I study of 5-fluorouracil, leucovorin and levamisole.
Cancer chemotherapy and pharmacology 1997;39(4):300-6.
1997: H Ian Robins; D Rushing; ME Kutz; Kendra Tutsch; CL Tiggelaar; D Paul; David Spriggs; C Kraemer; W Gillis; Chris Feierabend; Rhoda Arzoomanian; W Longo; Dona Alberti; FR d'Oleire; R P Qu; George Wilding; James A Stewart
Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):158-64.
1996: C J McGinn; Keith A Kunugi; Kendra Tutsch; Chris Feierabend; Dona Alberti; Mary J Lindstrom; George Wilding; Rhoda Arzoomanian; Timothy J Kinsella
Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(8):1299-305.
1994: Joan H Schiller; B Storer; Kendra Tutsch; Rhoda Arzoomanian; Dona Alberti; Chris Feierabend; David Spriggs
A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
Seminars in oncology 1994;21(5 Suppl 8):9-14.
1994: Joan H Schiller; B Storer; Kendra Tutsch; Rhoda Arzoomanian; Dona Alberti; Chris Feierabend; David Spriggs
Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(2):241-8.
1993: H Ian Robins; J D Cohen; C L Schmitt; Kendra Tutsch; Chris Feierabend; Rhoda Arzoomanian; Dona Alberti; FR d'Oleire; W Longo; C Heiss
Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(9):1787-94.